Last reviewed · How we verify
GTP regimen
GTP is a chemotherapy regimen combining gemcitabine, docetaxel, and cisplatin to inhibit cancer cell proliferation through multiple mechanisms.
GTP is a chemotherapy regimen combining gemcitabine, docetaxel, and cisplatin to inhibit cancer cell proliferation through multiple mechanisms. Used for Gastric cancer (Phase 3 development).
At a glance
| Generic name | GTP regimen |
|---|---|
| Sponsor | Beijing Friendship Hospital |
| Drug class | Combination chemotherapy regimen |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
GTP is a combination chemotherapy regimen where gemcitabine acts as an antimetabolite, docetaxel functions as a microtubule stabilizer, and cisplatin acts as an alkylating agent. Together, these three agents target cancer cells through complementary mechanisms to enhance cytotoxic effects.
Approved indications
- Gastric cancer (Phase 3 development)
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea and vomiting
- Peripheral neuropathy
- Nephrotoxicity
Key clinical trials
- A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis (PHASE2)
- APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma (PHASE1, PHASE2)
- GTP Regimen in the Treatment of Refractory/Recurrent HLH (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GTP regimen CI brief — competitive landscape report
- GTP regimen updates RSS · CI watch RSS
- Beijing Friendship Hospital portfolio CI